FAQ

refractory plasma cell neoplasm

Known as: Refractory Multiple Myeloma, Refractory Plasma Cell Myeloma, plasma cell neoplasm, refractory 
A plasma cell neoplasm that is resistant to treatment.
National Institutes of Health

Topic mentions per year

Topic mentions per year

1990-2017
0102019902017

Related topics

Related topics

34 relations
AnemiaAtypical lymphocyteB lymphoblastB-Lymphocytes
(More)

Related mentions per year

Related mentions per year

1936-2018
19401960198020002020
refractory plasma cell neoplasm
cancer cell
B-Lymphocytes
Anemia
Lymphocyte
Lymphoid Tissue

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells.
PURPOSE The onset of drug resistance is a major cause of treatment failure in multiple myeloma. Although increasing evidence is… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2016
2016
Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma.
PURPOSE Evaluate the safety, pharmacokinetic profile, pharmacodynamic effects, and antitumor activity of the first-in-class… (More)
Is this relevant?
2016
2016
Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma.
PURPOSE Tabalumab, a human mAb that neutralizes B-cell-activating factor (BAFF), demonstrated antitumor activity in xenograft… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2015
Highly Cited
2015
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
BACKGROUND Elotuzumab, an immunostimulatory monoclonal antibody targeting signaling lymphocytic activation molecule F7 (SLAMF7… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
Is this relevant?
2015
2015
Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma.
This single institution, open label Phase I-II dose escalation trial evaluated the safety and efficacy of the combination of… (More)
Is this relevant?
2015
2015
CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon.
CD38 is a type II transmembrane glycoprotein that is highly expressed in multiple myeloma and is a promising target for… (More)
  • figure 1
Is this relevant?
2015
2015
Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized…
BACKGROUND Health-related quality of life (HRQoL) is an important element for consideration in treatment decisions in patients… (More)
Is this relevant?
2013
2013
Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma.
BACKGROUND Newer systemic therapies have significantly advanced the treatment of multiple myeloma, but additional agents are… (More)
Is this relevant?
2013
2013
Lenalidomide in Combination with Dexamethasone in Elderly Patients with Advanced, Relapsed or Refractory Multiple Myeloma and Renal Failure
Salvage therapy of elderly patients with advanced, relapsed and refractory multiple myeloma (MM) is often limited by poor marrow… (More)
  • table 1
  • figure 1
  • table 2
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide.
MV-NIS is an oncolytic measles virus encoding the human thyroidal sodium iodide symporter (NIS). Here, we report the results of… (More)
Is this relevant?